A McLennan1, M Kerba2, U Subnis1, T Campbell1, L E Carlson1. 1. Department of Psychosocial Oncology, Holy Cross Cancer Centre, University of Calgary, Calgary, AB. 2. Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB.
Abstract
Background: Limited research has been conducted about the perspectives of oncology health care providers (hcps) concerning the use of cannabis in cancer care and their potential role in advising patients. We sought to determine the barriers encountered by hcps with respect to medical cannabis and their preferred practices in this area. Methods: An anonymous survey about cannabis was distributed to oncology hcps at the Tom Baker Cancer Centre in Calgary, Alberta. The 45-question survey measured the opinions of hcps about cannabis use and authorization in oncology. Results: Of 103 oncology hcps who participated in the study, 75% were women. By hcp type, the most commonly reported professional groups were oncology nurse (40%), radiation therapist (9%), and pharmacist (6%). Of respondents, 75% reported providing direct care to cancer patients. More than half (69%) had spoken to a patient about cannabis in the preceding month, and 84% believed that they lacked sufficient knowledge about cannabis to make recommendations. Barriers such as monitoring the patient's use of cannabis (54%), prescribing an accurate dose (61%) or strain (53%), and having insufficient research (50%) were most commonly reported. More than half of hcps (53%) would be interested in receiving more information or training about the use of cannabis in oncology. Conclusions: The survey indicated that this group of oncology hcps believed that they lacked sufficient knowledge about cannabis to make recommendations to patients. In addition to that lack of knowledge, a number of notable barriers were reported, and more than half the hcps indicated interest in learning more about cannabis in the future. 2020 Multimed Inc.
Background: Limited research has been conducted about the perspectives of oncology health care providers (hcps) concerning the use of cannabis in cancer care and their potential role in advising patients. We sought to determine the barriers encountered by hcps with respect to medical cannabis and their preferred practices in this area. Methods: An anonymous survey about cannabis was distributed to oncology hcps at the Tom Baker Cancer Centre in Calgary, Alberta. The 45-question survey measured the opinions of hcps about cannabis use and authorization in oncology. Results: Of 103 oncology hcps who participated in the study, 75% were women. By hcp type, the most commonly reported professional groups were oncology nurse (40%), radiation therapist (9%), and pharmacist (6%). Of respondents, 75% reported providing direct care to cancerpatients. More than half (69%) had spoken to a patient about cannabis in the preceding month, and 84% believed that they lacked sufficient knowledge about cannabis to make recommendations. Barriers such as monitoring the patient's use of cannabis (54%), prescribing an accurate dose (61%) or strain (53%), and having insufficient research (50%) were most commonly reported. More than half of hcps (53%) would be interested in receiving more information or training about the use of cannabis in oncology. Conclusions: The survey indicated that this group of oncology hcps believed that they lacked sufficient knowledge about cannabis to make recommendations to patients. In addition to that lack of knowledge, a number of notable barriers were reported, and more than half the hcps indicated interest in learning more about cannabis in the future. 2020 Multimed Inc.
Authors: Ngaire King; Lynda G Balneaves; Gregory T Levin; Thao Nguyen; Jill G Nation; Cynthia Card; Tracy Truant; Linda E Carlson Journal: Integr Cancer Ther Date: 2015-06-11 Impact factor: 3.279
Authors: Anastasia B Evanoff; Tiffany Quan; Carolyn Dufault; Michael Awad; Laura Jean Bierut Journal: Drug Alcohol Depend Date: 2017-09-04 Impact factor: 4.492
Authors: Ilana M Braun; Alexi Wright; John Peteet; Fremonta L Meyer; David P Yuppa; Dragana Bolcic-Jankovic; Jessica LeBlanc; Yuchiao Chang; Liyang Yu; Manan M Nayak; James A Tulsky; Joji Suzuki; Lida Nabati; Eric G Campbell Journal: J Clin Oncol Date: 2018-05-10 Impact factor: 44.544
Authors: Helen McTaggart-Cowan; Colene Bentley; Adam Raymakers; Rebecca Metcalfe; Philippa Hawley; Stuart Peacock Journal: Cancer Med Date: 2020-10-17 Impact factor: 4.452
Authors: Billy Vinette; José Côté; Ali El-Akhras; Hazar Mrad; Gabrielle Chicoine; Karine Bilodeau Journal: BMC Cancer Date: 2022-03-24 Impact factor: 4.430